Concomitant trastuzumab with thoracic radiotherapy: A morphological and functional study

Annals of Oncology

Volumn 22, Issue 5, 2011, Pages 1120-1126

  Yavas, G ^a   Yildiz, F ^a   Guler, S ^a   Sargon, M F ^a   Yildiz, D ^a   Yolcu, T ^a   Tuncer, M ^a   Akyol, F H ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Radiotherapy; Trastuzumab; Vascular damage

Indexed keywords

TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; FEMALE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOTHERAPY; RAT; SUBENDOTHELIUM; THORACIC AORTA; THORAX; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION;

EID: 79955500305     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq590     Document Type: Article

References (43)

1. Gassmann A. Zur Histologie der Rö ntgenulceria. Fortschr Geb Roentgenstr 1898; 2: 199-207.
2. Gold H. Production of arteriosclerosis in the rat: effect of x-ray and a high-fat diet. Arch Pathol Lab Med. 1961; 71: 268-273.
3. Lindsay S, Kohn HI, Dakin RL et al. Aortic arteriosclerosis in the dog after localized aortic x-irradiation. Circ Res 1962; 10: 51-60.
4. Lamberts HD, de Boer WGRM. Contributions to the study of immediate and early x-ray reactions with regard to chemoprotection: VII. X-ray-induced atheromatous lesions in the arterial wall of cholestrolemic rabbits. Int J Radiat Biol 1965; 9: 165-174.
5. Zidar N, Ferlugo D, Haula A et al. Contribution to the pathogenesis of radiation-induced injury to large arteries. J Laryngol Otol 1997; 111: 988-999.
6. Murros EK, Toole JF. The effect of radiation on carotid arteries: a review article. Arch Neurol 1989; 46: 449-455.
7. Rubin BD. The Radiation Biology of the Vascular Endothelium, 1st edition. CRC Press, Chapman and Hall 1998.
8. Adams MJ, Hardenbergh PH, Constine SL, Liphultz SE. Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 2003; 45: 55-75.
9. Stewart JR, Fajardo LF, Gilette SM, Constine SL. Radiation injury to the heart. Int J Radiat Oncol Biol Phys 1995; 31(5): 1205-1211.
10. Stewart JR, Fajardo LF. Radiation induced heart disease. Clinical and experimental aspects. Radiol Clin North Am 1971; 9: 511-531.
11. Benz CC, O'Hagen RC, Richter B et al. HER2/neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancer. Oncogene 1997; 15: 1513-1525.
12. Wonders KY, Reigie BS. Trastuzumab and doxorubicin related cardiotoxicity and the cardioprotective role of exercise. Integr Cancer Ther 2009; 8: 17-21.
13. Albanell J, Bellmunt J, Moline R et al. Node negative breast cancers with p53 (-)/HER2-neu status may identify women with very good prognosis. Anticancer Res 1996; 16: 1027-1032.
14. Perez EA, Suman VJ, Davidson N et al. NCCTG N9831, May 2005 update Presented at the 45th annual meeting of the American Society of Clinical Oncology Orlando FL, May 16, 2005.
15. Romond EH, Perez EA, Bryan J et al. Trastuzumab plus adjuvant chemotherapy for operable HER-2 positive breast cancer. N Engl J Med 2005; 353: 1673-1684.
16. Smith I, Procter M, Gelber RD et al. 2-Year follow-up of trastuzumab after adjuvant chemotherapy in HER-2 positive breast cancer: a randomized controlled trial. Lancet 2007; 369: 29-36.
17. Slamon D, Eiermann W, Robert N et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER-2/nue positive early breast cancer patients. In Proceedings of the 29th Annual San Antonio Breast Cancer Symposium, San Antonio TX, December 14-17, 2006. Abstract.
18. Joensuu H, Kellokumpu-Lehtienen PL, Bono P et al. Adjuvant docetaxel or vineralbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820.
19. Halyard MY, Pisansky TM, Dueck AC et al. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG phase III trial N9831. J Clin Oncol 2009; 27(16): 2638-2644.
20. Vogel C, Cobleigh MA, Triphaty DA et al. Adjuvant docetaxel or vineralbine with or without trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 719-726.
21. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 2001; 344: 783-792.
22. Leyland Jones B, Gelmon K, Ayoub JP et al. Pharmacokinetics, safety and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-3971.
23. L̈ scher TF, Vanhoutte PM. Endothelium-dependent contractions to acetylcholine in the aorta of the spontaneously hypertensive rat. Hypertension 1986; 8(4): 344-348.
24. Emir M, Gol MK, Ozisik K et al. Harvesting techniques affect the integrity of the radial artery: an electron microscopic evaluation. Ann Thorac Surg 2004; 78: 1319-1325.
25. Hasenfuss G. Animal models of human cardiovascular disease, heart failure and hypertrophy. Cardiovasc Res 1998; 39: 60-76.
26. Verbeke M, Thierens H, Toeymans Y, De Ridder L. An organotypical in vitro model for vascular tissue remodeling and its application to study radiation effects. Cytotechnology 2000; 34: 185-195.
27. Crocker IR. Endovascular gamma irradiation in the swine model: the Emory experience. In King SB, Walksman R, Crocker I (eds), Discoveries in Radiation for Restenosis, Abstract Book of Course at Lenox Atlanta, GA, USA 1996; 37-38.
28. Brenner DJ, Miller RC, Hall EJ. The radiobiology of intravascular irradiation. Int J Radiat Oncol Biol Phys 1999; 36: 805-810.
29. Serruys PW, Carlier SG. The scope of the problem of vascular restenosis. In Levandag PC (ed), Vascular Brachytherapy. New Perspectives. Remedica Publishing, London 1999; 4-7.
30. Shaffer U, Micke O, Dorszewki A et al. External beam irradiation inhibits neointimal hyperplasia after injury-induced arterial smooth muscle cell proliferation. Int J Radiat Oncol Biol Phys 1998; 42: 617-622.
31. Weinberger J, Simon AD. Intracoronary irradiation fort he prevention of restenosis. Curr Opin Cardiol 1997; 12: 468-474.
32. Brenner DJ. The linear quadratic model is an appropriate methodology for determining isoeffective doses at large doses per fraction. Semin Radiat Oncol 2008; 8: 234-239.
33. Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high risk breast cancer receiving adjuvant chemotherapy: 20 year results of British Colombia randomized trial. J Natl Cancer Inst 2005; 97: 116-126.
34. Host H, Breenhovd I, Loeb M. Postoperative radiotherapy in breast cancer long term results from the Oslo study. Int J Radiat Oncol Biol Phys 1986; 12: 727-732.
35. Darby SC, Cutter DJ, Boerma M et al. Radiation related heart disease: current knowledge and future perspectives. Int J Radiat Oncol Biol Phys 2010; 76: 656-665.
36. Veinot JP, Edward WD. Pathology of radiation-induced heart disease: a surgical and autopsy study of 27 cases. Hum Pathol 1996; 8: 766-773.
37. Boivin JF, Hutchison GB, Lubin JH et al. Coronary artery disease mortality in patients treated for Hodgkin's disease. Cancer 1992; 69: 1241-1242.
38. Darby SC, McGale P, Taylor CW et al. Long-term mortality from heart disease ad lung cancer after radiotherapy for early breast cancer. Prospective cohort study of about 300000 women in US SEER cancer registries. Lancet Oncol 2005; 6: 557-565.
39. Hudis AC. Trastuzumab-mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39-51.
40. Yarden Y. The EGFR family and its ligands in human cancer: signaling mechanism and therapeutic opportunities. J Clin Oncol 2009; 18: 3471-3479.
41. Valabrega G, Montemurro F, Agiletta M. Trastuzumab mechanism of action, resistance and future perspectives in HER-2 overexpressing breast cancer. Ann Oncol 2007; 18: 977-984.
42. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxeli carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94: s5.
43. Shaffer R, Tyldesley S, Rolles M et al. Acute cardiotoxicity with concurrent trastuzumab and radiotherapy including internal mammary chain nodes: a retrospective single-institution study. Radiother Oncol 2009; 90: 122-126.